Neighborhood disadvantage, or living in a poorer region, was linked to significantly shorter survival time for ALS patients ...

A mishap with her ankle-foot orthoses was discouraging, but columnist Dagmar Munn quickly happened upon the "mini-miracles" that followed.

A trial that will test a noninvasive device called MyoRegulator as a treatment for ALS was cleared to start enrolling ...

IFB-088 (icerguastat) was safe and significantly slowed disease progression in certain people with ALS in a Phase 2 clinical trial.

After more than a decade of living with her husband's ALS, columnist Kristin Neva has found the equipment to be helpful in ...

Repeated brain injury resulted in SOD1-ALS mice showing greater weight loss, an earlier tremor in the hind limbs, and ...

Ncardia’s iPSC-derived microglia may aid ALS research and help to screen new therapies that target inflammation in ALS.

Qure is planning soon to start enrolling patients in a second dose group as part of a clinical trial testing AMT-162 for SOD1 ...

Neuropeutics is collaborating with LifeArc on a small molecule therapy that reportedly lowered TDP-43 clumping in an animal ...

Masitinib is an oral inhibitor of tyrosine kinases, enzymes important for immune cells thought to drive ALS inflammation and ...

Looking for an online ALS group? Columnist Dagmar Munn has you covered with helpful tips gleaned from years as a forums co-moderator.